Incyte Corporation - Common Stock (NQ:INCY)

113.31 -2.40 (-2.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have...

Via Talk Markets

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In...

Via Benzinga

Topics Stocks

Expert Ratings For Incyte ↗

November 19, 2021

Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Expert Ratings For Incyte ↗

September 23, 2021

Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

Stocks Most Impacted by 7-10 Year Treasuries ↗

November 17, 2021

A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value.

Via Talk Markets

Topics Stocks

Incyte to Present at Upcoming Investor Conference

November 09, 2021

From Incyte

Via Business Wire

More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

November 04, 2021

From Incyte

Via Business Wire

Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

INCY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 02, 2021

From Incyte

Via Business Wire

A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus ↗

November 02, 2021

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will...

Via Benzinga

Topics Economy

Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas ↗

November 01, 2021

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),...

Via Benzinga

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

November 01, 2021

From Incyte

Via Business Wire

Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

November 01, 2021

From Incyte

Via Business Wire

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

October 28, 2021

From Incyte

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays ↗

October 27, 2021

It's much too early to count these companies out.

Via The Motley Fool

Could This Be the Next Blockbuster Indication for Eli Lilly? ↗

October 21, 2021

Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.

Via The Motley Fool

Incyte to Report Third Quarter Financial Results

October 13, 2021

From Incyte

Via Business Wire

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

October 02, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Incyte Names New Member to Its Board of Directors

September 28, 2021

From Incyte

Via Business Wire

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate ↗

September 27, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...

Via Benzinga

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America ↗

September 23, 2021

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...

Via Benzinga

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.